<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820466</url>
  </required_header>
  <id_info>
    <org_study_id>GRAY-ZONE</org_study_id>
    <nct_id>NCT03820466</nct_id>
  </id_info>
  <brief_title>Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin</brief_title>
  <acronym>GRAY-ZONE</acronym>
  <official_title>Investigator-initiated, Placebo-controlled, Randomized Trial to Assess the Efficacy and Safety of Platelet Inhibition and/ or Lipid Lowering in Non-ACS-patients With Elevated High-sensitivity Troponin Values</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Mahir Karakas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of platelet inhibition and / or lipid lowering in
      non-ACS-patients with symptoms suggestive for ACS, and elevated high-sensitivity troponin
      values
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current databases show, that high-/ ultra sensitive (hs)/ (us) troponin levels above the 99th
      percentile in patients presenting with chest pain are indicative for future cardiovascular
      events, even when acute coronary syndrome (ACS) was ruled out. Most of these non-ACS-patients
      are discharged without specific/ preventive therapy (anti-platelet or anti-lipid), although
      &quot;positive&quot; troponin values (any value at any time during hospitalisation above the 99th
      percentile) seem to clearly indicate underlying myocardial ischemia. In summary, there is an
      unmet need and huge potential to reduce mortality and morbidity in Chest Pain Unit patients
      by specific therapy. The investigators propose that platelet inhibition by Aspirin or lipid
      lowering by Atorvastatin will prevent plaque rupture and superimposition of thrombosis to
      coronary atherosclerosis in this population. It is planned to conduct a controlled clinical
      trial: 3,000 troponin positive patients presenting at emergency room (ER)/ CPU with symptoms
      suggestive for ACS, but an ACS was ruled out, will be assigned randomly to Aspirin 100 mg
      and/ or Atorvastatin 20 mg versus placebo (2x2 factorial design).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarction and/ or cardiovascular death and/ or revascularization</measure>
    <time_frame>Until last patient has completed 12 months of follow-up</time_frame>
    <description>Time to myocardial infarction, coronary revascularization, or death, whatever comes first</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Acute Chest Syndrome</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg once daily and Placebo Atorvastatin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20 mg once daily and Placebo Aspirin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 100 mg once daily and Atorvastatin 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Aspirin once daily and Placebo Atorvastatin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Once daily application of platelet inhibiting medication</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <other_name>Acetyl Salicyl Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Once daily application of lipid lowering medication</description>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Aspirin</intervention_name>
    <description>Once daily application of placebo</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Atorvastatin</intervention_name>
    <description>Once daily application of placebo</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with symptoms suggestive for ACS presenting within 48 hours after onset in the
             ER/ Chest Pain Unit (CPU)

          -  Patient has at least one elevated high-sensitivity troponin I or T value

          -  Chest pain is classified as non-ACS, despite elevated hsTn (e.g. because of missing
             troponin dynamics)

          -  At least 50 years of age

        Exclusion Criteria:

          -  Indication for antiplatelet therapy (e.g transient ischemic attack, or stable coronary
             artery diseases -CAD) or anticoagulation therapy (such as atrial fibrillation)

          -  Indication for anti-lipid therapy

          -  Any evidence of an acute myocardial necrosis (e.g imaging evidence of new regional
             wall motion abnormality, or significant ST-segment-T wave (ST-T) changes in ECG)

          -  Untreated clinically significant CAD requiring revascularization

          -  Hemoglobin value below 8 mg/d, and/or creatinine kinase ≥3 times ULN, and/or AST or
             ALT ≥3 times ULN

          -  Active malignancy of any organ system, treated or untreated. Subjects have to be in
             remission for at least 36 months to be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD</last_name>
    <phone>+4915222817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Berlin, Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulf Landmesser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD, MBA</last_name>
      <phone>+4915222817493</phone>
      <email>m.karakas@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mirjam Kessler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Mahir Karakas</investigator_full_name>
    <investigator_title>Coordinating Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Troponin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Chest Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

